Los Angeles, CA, United States of America

Justin Golovato

This inventor holds 13 USPTO granted patents and 2 published patent applications, plus 2 CIPO patents and 3 EPO patents, primarily in Biopharmaceutical Research. Top assignees: Nant Holdingsip, LLC, Chan Soon-Shiong Nanthealth Foundation, Nantbio, Inc.. Active years: 2014-2020.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Justin Golovato. Retrieved from https://idiyas.com/inventor/justin-golovato

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank

USPTO Granted Patents = 13 (Patent Applications = 2)

% Patents Active = 100.0

CIPO Patents = 2 (Patent Applications = 1)

EPO Patents = 3 (Patent Applications = 3)

Average Co-Inventor Count = 6.0

ph-index = 3

Forward Citations = 35(Granted Patents)

Company Filing History:

Chan Soon-Shiong Nanthealth Foundation

where one patent can have more than one assignee

Years Active: 2014-2020

Loading Chart...

Areas of Expertise:

K-Ras

Wound Healing

Influenza A

RNA Polymerase

Calcium Flux Agonists

Small Molecule Inhibitors

Compositions

Methods

13 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 10668076 - Compositions and methods of targeting mutant K-Ras (2020-06-02),

2. 10487078 - Compositions and methods of targeting mutant K-RAS (2019-11-26),

3. 10434142 - Compositions and methods of improved wound healing (2019-10-08),

4. 10350225 - Small molecule inhibitors of influenza A RNA-dependent RNA polymerase (2019-07-16),

5. 10076529 - Small molecule inhibitors of influenza A RNA-dependent RNA polymerase (2018-09-18),

6. 9987282 - Small molecule inhibitors of influenza A RNA-dependent RNA polymerase (2018-06-05),

7. 9884087 - Compositions and methods of improved wound healing (2018-02-06),

8. 9750805 - Calcium flux agonists and methods therefor (2017-09-05),

9. 9687491 - Compositions and methods of targeting mutant K-Ras (2017-06-27),

10. 9463184 - Calcium flux agonists and methods thereof (2016-10-11),

11. 9422291 - Small molecule inhibitors of influenza A RNA-dependent RNA polymerase (2016-08-23),

12. 9315464 - Small molecule inhibitors of influenza A RNA-dependent RNA polymerase (2016-04-19),

13. 8633198 - Small molecule inhibitors of influenza A RNA-dependent RNA polymerase (2014-01-21),

Title: Justin Golovato: A Pioneer of Innovation in Targeting Mutant K-Ras for a Better Future

Introduction:

In the fast-paced world of invention and innovation, individuals like Justin Golovato stand out for their relentless pursuit of groundbreaking solutions with a positive impact on society. Based in Los Angeles, CA, Justin Golovato has established himself as a true pioneer in the field of inventions, inspiring the next generation of inventors and entrepreneurs.

Latest Patents:

Justin Golovato's latest patents showcase his dedication to advancing scientific research and medical breakthroughs. His patents on "Compositions and methods of targeting mutant K-Ras" focus on modeling K-Ras proteins with mutations to inhibit interactions among activated K-Ras proteins and their effectors. Specifically, his work targets the G12D mutant form, a significant step in developing treatments for related conditions.

Career Highlights:

With a total of 13 patents to his name, Justin Golovato's career highlights are a testament to his innovative spirit and impact on the world. Throughout his journey, he has worked with esteemed organizations such as Nant Holdingsip, LLC and the Chan Soon-Shiong Nanthealth Foundation, contributing significantly to cutting-edge research and development in the medical field.

Collaborations:

Collaboration is key to driving innovation forward, and Justin Golovato has had the privilege of working alongside talented individuals like Kayvan R Niazi and Shahrooz Rabizadeh. Together, they have shared expertise, resources, and a common vision to create meaningful change through their inventions and patents.

Conclusion:

In conclusion, Justin Golovato's unwavering commitment to innovation and his groundbreaking work in targeting mutant K-Ras proteins exemplify his status as a true pioneer in the field of inventions. His efforts continue to inspire others to think outside the box, push boundaries, and strive for a better future through inventions that make a difference.

Profile summary based on public USPTO records.